rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Q/C Technologies, Inc.

QCLS · Nasdaq

Health CareDiagnostics & LabsNot moving yet

QCLS stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 83.0% below that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+5 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
52% +5 in 4 wk
Insider buys, 12 months
$11K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
19 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

21 Apr – 20 Oct
16%34%53%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$11KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Chelsea Sierra VossDirectorbought1,753at $3.1530 Mar 2026filed 14 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders19+4 on the quarter
New · exited6 · 2
Reported value$2.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Quinn Opportunity Partners LLCreduced · filed 14 Aug 2026123,024$480K-88,366−41.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026115,031$449K+77,520+206.7%
JANE STREET GROUP, LLCreduced · filed 14 Aug 202687,241$340K-38,947−30.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202670,682$276K+23,292+49.1%
UBS Group AGreduced · filed 13 Aug 202658,894$230K-19,095−24.5%
Balyasny Asset Management L.P.new · filed 14 Aug 202657,692$225K+57,692
ADAR1 Capital Management, LLCunchanged · filed 14 Aug 202650,000$195K00.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202643,053$168K+27,498+176.8%
STATE STREET CORPadded · filed 7 Aug 202625,305$99K+12,400+96.1%
DIMENSIONAL FUND ADVISORS LPunchanged · filed 11 Aug 202619,058$74K00.0%
30 Sep 2025 – 30 Jun 2026
101519Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Joshua Silverman Company insiderExecutive Chairman · last 1 Oct 20262 · 0
Billy Joe White Company insiderDirector · last 13 Apr 20260 · 0
Bruce Bernstein Company insiderDirector · last 13 Apr 20260 · 0
Chelsea Sierra Voss Company insiderDirector · last 13 Apr 20261 · 0
Mitchell Glass Company insiderChief Medical Officer · last 13 Apr 20260 · 0
Stephen Friscia Company insiderDirector · last 13 Apr 20260 · 0
Gary M. Rauch Company insiderOther · last 14 Nov 20252 · 0
Pharmacyte Biotech, Inc. Company insider10% owner · last 14 Nov 20250 · 0
Ian Rhodes Company insiderInterim CFO · last 17 Apr 20250 · 0
Paul Rivard Company insiderChief Legal Officer · last 24 Aug 20234 · 0
Adam Kaplin Company insiderChief Scientific Officer · last 7 Jun 20230 · 0
Christopher C. Chapman, Jr. Company insiderPresident, Chief Med. Officer · last 7 Jun 20230 · 0

Same industry

CDNA CareDxLeading+94%
NTRA NateraLeading+49%
FTRE Fortrea HoldingsLeading+42%
XGN ExagenLeading+41%
TKNO Alpha TeknovaLeading+36%
PSNL PersonalisLeading+36%
ADPT Adaptive BiotechnologiesLeading+21%
GH Guardant HealthLeading+20%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-27.6%
Share count trendFY 2025 · to 12 Apr 20262.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$987K
Free cash flowFY 2025 · to 31 Dec 2025−$10.8M

Analyst forecasts

No analyst forecasts yet.